SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
China Galaxy Securities: Investing in Three Main Themes in the Hong Kong Stock Market Amid Geopolitical Conflicts and High Oil Prices
New stocks interpretation | With a 1193.68 times oversubscription, can the rapid innovation of Feisu (03355) DTC model support a premium for "hard technology"?
Sinolink: Domestic computing power is accelerating throughout the full chain, with the potential for both quantity and price to rise together.
China Galaxy Securities: Investing in Three Main Themes in the Hong Kong Stock Market Amid Geopolitical Conflicts and High Oil Prices
New stocks interpretation | With a 1193.68 times oversubscription, can the rapid innovation of Feisu (03355) DTC model support a premium for "hard technology"?
Sinolink: Domestic computing power is accelerating throughout the full chain, with the potential for both quantity and price to rise together.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
